Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nijmegen breakage syndrome protein 1 (nibrin; NBN) is a key DNA repair protein encoded by the NBN gene, functioning as a core adapter in the MRN complex together with MRE11 and RAD50[1][3]. This complex is essential for recognizing and repairing DNA double-strand breaks, activating checkpoint signaling, maintaining chromosomal stability, and promoting homologous recombination and telomere integrity[1][3]. Nibrin mediates recruitment of repair proteins to DNA damage sites, and is required for critical processes like immunoglobulin class-switch recombination in B lymphocytes[2]. Mutations in NBN cause Nijmegen breakage syndrome, an autosomal recessive disorder distinguished by microcephaly, cancer predisposition, immunodeficiency, and sensitivity to ionizing radiation[3]. Nibrin is not an enzyme or receptor, but is considered a valid therapeutic target in cancer research and genetic diagnostics[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nijmegen breakage syndrome protein 1 (NBN).